3-(4-氯苯基)-2-羟基丙-2-烯酸 | 127273-12-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(4-氯苯基)-2-羟基丙-2-烯酸
• 英文名称: 3-(4-chlorophenyl)-2-hydroxyacrylic acid
• 英文别名: 3-(4-Chlorophenyl)-2-hydroxyprop-2-enoic acid
• CAS: 127273-12-5
• 化学式: C₉H₇ClO₃
• 分子量: 198.606
• InChiKey: LJIZTSRZWZUBJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-氯苯基)-2-羟基丙-2-烯酸 在 sodium tetrahydroborate 、 乙酰氯 作用下， 以 乙醇 为溶剂， 反应 0.5h， 生成 3-(4-氯-苯基)-丙烷-1,2-二醇
  参考文献：
  名称：

  Chemocontrolled reduction of aromatic α-ketoesters by NaBH4: Selective synthesis of α-hydroxy esters or 1,2-diols

  摘要：

  alpha-hydroxyesters 5a-g or diols 6a-g have been obtained in high yields by reduction of aromatic alpha-ketoesters 4 once or twice respectively by using NaBH4 as the reducer under suitable conditions. The use of a solvent that does not interact with the reagent allowed the double reduction to occur with only a slight excess of borohydride in very mild conditions. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(97)00154-8
• 作为产物：
  描述：

  2-methyl-4-(4-chlorobenzylidene)-4H-oxazol-5-one 在 盐酸 作用下， 生成 3-(4-氯苯基)-2-羟基丙-2-烯酸
  参考文献：
  名称：

  Chemocontrolled reduction of aromatic α-ketoesters by NaBH4: Selective synthesis of α-hydroxy esters or 1,2-diols

  摘要：

  alpha-hydroxyesters 5a-g or diols 6a-g have been obtained in high yields by reduction of aromatic alpha-ketoesters 4 once or twice respectively by using NaBH4 as the reducer under suitable conditions. The use of a solvent that does not interact with the reagent allowed the double reduction to occur with only a slight excess of borohydride in very mild conditions. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(97)00154-8

文献信息

• Evaluation of α-hydroxycinnamic acids as pyruvate carboxylase inhibitors
  作者：Daniel J. Burkett、Brittney N. Wyatt、Mallory Mews、Anson Bautista、Ryan Engel、Chris Dockendorff、William A. Donaldson、Martin St. Maurice

  DOI：10.1016/j.bmc.2019.07.027

  日期：2019.9

  5 μM respectively. Compound 8v is a competitive inhibitor with respect to pyruvate (Ki = 0.74 μM) and a mixed-type inhibitor with respect to ATP, indicating that it targets the unique carboxyltransferase (CT) domain of PC. Furthermore, compound 8v does not significantly inhibit human carbonic anhydrase II, matrix metalloproteinase-2, malate dehydrogenase or lactate dehydrogenase.

  通过基于结构的药物设计项目（SBDD），发现了有效的丙酮酸羧化酶小分子抑制剂（PC）。制备了一系列α-酮酸（7）和α-羟基肉桂酸（8），并在两种测定中评估了其对PC的抑制作用。两种最有效的抑制剂是3,3'-（1,4-亚苯基）双[2-羟基-2-丙酸]（8u）和2-羟基-3-（喹啉-2-基）丙酸（8v））的IC 50值分别为3.0±1.0μM和4.3±1.5μM。化合物8v是相对于丙酮酸（K i = 0.74μM）和针对ATP的混合型抑制剂，表明它靶向PC的独特羧基转移酶（CT）域。此外，化合物8v不会显着抑制人碳酸酐酶II，基质金属蛋白酶-2，苹果酸脱氢酶或乳酸脱氢酶。
• Method of treating resistant tumors
  申请人：Wyeth Holdings Corporation

  公开号：US20040121965A1

  公开（公告）日：2004-06-24

  The invention provides a method of treating or inhibiting the growth of or eradicating a tumor in a mammal in need thereof wherein said tumor is resistant to at least one chemotherapeutic agent which method comprises providing to said mammal an effective amount of a compound of Formula II or a pharmaceutically acceptable salt thereof.

  本发明提供了一种治疗或抑制哺乳动物体内对至少一种化疗药物产生耐药性的肿瘤生长或根除肿瘤的方法，该方法包括向该哺乳动物提供有效量的公式II化合物或其药学上可接受的盐。
• Structure–activity relationship study of 4EGI-1, small molecule eIF4E/eIF4G protein–protein interaction inhibitors
  作者：Khuloud Takrouri、Ting Chen、Evangelos Papadopoulos、Rupam Sahoo、Eihab Kabha、Han Chen、Sonia Cantel、Gerhard Wagner、Jose A. Halperin、Bertal H. Aktas、Michael Chorev

  DOI：10.1016/j.ejmech.2014.03.034

  日期：2014.4

  Protein-protein interactions are critical for regulating the activity of translation initiation factors and multitude of other cellular process, and form the largest block of untapped albeit most challenging targets for drug development. 4EGI-1, (E/Z)-2-(2-(4-(3,4-dichlorophenyl)thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic acid, is a hit compound discovered in a screening campaign of small molecule libraries as an inhibitor of translation initiation factors elF4E and eIF4G protein protein interaction; it inhibits translation initiation in vitro and in vivo. A series of 4EGI-1-derived thiazol-2-yl hydrazones have been designed and synthesized in order to delineate the structural latitude and improve its binding affinity to eIF4E, and increase its potency in inhibiting the eIF4E/eIF4G interaction. Probing a wide range of substituents on both phenyl rings comprising the 3-phenylpropionic acid and 4-phenylthiazolidine moieties in the context of both E- and Z-isomers of 4EGI-1 led to analogs with enhanced binding affinity and translation initiation inhibitory activities. (C) 2014 Elsevier Masson SAS. All rights reserved.
• Design, synthesis, and biological evaluation of substrate-competitive inhibitors of C-terminal Binding Protein (CtBP)
  作者：Sudha Korwar、Benjamin L. Morris、Hardik I. Parikh、Robert A. Coover、Tyler W. Doughty、Ian M. Love、Brendan J. Hilbert、William E. Royer、Glen E. Kellogg、Steven R. Grossman、Keith C. Ellis

  DOI：10.1016/j.bmc.2016.04.037

  日期：2016.6

  C-terminal Binding Protein (CtBP) is a transcriptional co-regulator that downregulates the expression of many tumor-suppressor genes. Utilizing a crystal structure of CtBP with its substrate 4-methylthio-2-oxobutyric acid (MTOB) and NAD(+) as a guide, we have designed, synthesized, and tested a series of small molecule inhibitors of CtBP. From our first round of compounds, we identified 2-(hydroxyimino)-3-phenylpropanoic acid as a potent CtBP inhibitor (IC50 = 0.24 mu M). A structure-activity relationship study of this compound further identified the 4-chloro- (IC50 = 0.18 mu M) and 3-chloro- (IC50 = 0.17 mu M) analogues as additional potent CtBP inhibitors. Evaluation of the hydroxyimine analogues in a short-term cell growth/viability assay showed that the 4-chloro- and 3-chloro-analogues are 2-fold and 4-fold more potent, respectively, than the MTOB control. A functional cellular assay using a CtBP-specific transcriptional readout revealed that the 4-chloro- and 3-chloro-hydroxyimine analogues were able to block CtBP transcriptional repression activity. This data suggests that substrate-competitive inhibition of CtBP dehydrogenase activity is a potential mechanism to reactivate tumor-suppressor gene expression as a therapeutic strategy for cancer. (C) 2016 Elsevier Ltd. All rights reserved.
• [EN] METHOD OF TREATING RESISTANT TUMORS<br/>[FR] METHODE DE TRAITEMENT DE TUMEURS RESISTANTES
  申请人：WYETH CORP

  公开号：WO2004026293A2

  公开（公告）日：2004-04-01

  The invention provides a method of treating or inhibiting the growth of or eradicating a tumor in a mammal in need thereof wherein said tumor is resistant to at least one chemotherapeutic agents which method comprises providing to said mammal an effective amount of a compound of Formula II or a pharmaceutically acceptable salt thereof.